Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. The event takes place from November 29 to December 1, 2022, in New York City. CEO Dwight Egan and President Dr. Kirk Ririe will discuss recent advancements and the upcoming Co-Dx PCR diagnostic platform. The presentation will be available online at 11:30 AM Eastern Time on the day of the event. Additionally, one-on-one meetings for institutional investors will be coordinated with Company or Piper Sandler representatives.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announces its participation at the MEDICA 2022 trade fair in Düsseldorf, Germany, from November 15-17. This renowned event, the largest medical trade fair globally, attracts thousands of exhibitors from over 50 countries. Co-Dx aims to showcase its in vitro diagnostic products for COVID-19 and other infectious diseases, alongside its innovative CoPrimer™ technology. Attendees are encouraged to visit Booth 3D15 for more insights on the Company’s offerings, including the upcoming Co-Dx PCR Home platform.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported third quarter 2022 results with revenue of $5.1 million, a significant drop from $30.1 million in the prior year, but a slight increase of 1.4% from Q2. Gross profit was $4.3 million (84.9% of revenue), while operating loss reached $6.5 million, contrasting with a $13.6 million profit last year. The net loss was $1.4 million, down from $11.5 million profit previously. The company repurchased 2.9 million shares at an average price of $3.61. Despite lower COVID-19 test demand, progress on the Co-Dx PCR Home platform is promising, with clinical trials expected soon.
Co-Diagnostics (Nasdaq-CM: CODX) has announced its participation at the Association for Molecular Pathology (AMP) annual expo in Phoenix, AZ, from November 1-5. The event is a key gathering for molecular diagnostics professionals. Visitors can explore Co-Diagnostics' pioneering CoPrimer™ PCR technology and infectious disease products at booth #712. The expo starts at 12 pm PT on November 3. For further details, registration information is available here.
Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Dr. Mark Poritz as the new Chief Scientific Officer. Dr. Poritz is a seasoned molecular biologist with over 30 years of experience in molecular diagnostics, notably at BioFire Diagnostics. He has previously led significant developments, including the FilmArray platform. His appointment comes with an emphasis on enhancing the accessibility of innovative diagnostic solutions. The company also expresses gratitude to outgoing CSO Dr. Jesse Montgomery for his contributions.
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its third quarter 2022 results on November 10, 2022, after market close. The company will also host a conference call and webcast at 4:30 p.m. EDT to discuss financial outcomes with analysts and investors. Key management present will include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The event will be accessible via the company's website, with a recorded version available later for those unable to attend live.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will host a booth at Africa Health/Medlab Africa in Johannesburg, South Africa from October 26-28, 2022. This significant event brings together healthcare professionals from the South African Development Community and beyond, showcasing the latest in medical technology and services. Co-Diagnostics will present their innovative CoPrimer™ PCR technology and infectious disease products, alongside the upcoming Co-Dx PCR Home testing platform. Attendees can find registration details here.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in IDWeek 2022 in Washington, D.C. from October 19-23 and Asia Health/Medlab Asia in Bangkok, Thailand from October 19-21. These conferences aim to update professionals on infectious diseases and connect healthcare communities. Co-Diagnostics will showcase its CoPrimer™ PCR technology and upcoming Co-Dx PCR Home testing platform at both events. Attendees can find more information on registration at the respective conference websites.
Co-Diagnostics (Nasdaq-CM: CODX) is sponsoring and hosting a booth at the Caribbean Public Health Agency's 66th Annual Health Research Conference on September 15-17 in Jamaica. The theme this year is 'COVID-19 and Digital Health: Transforming, Connecting, Informing Public Health.' Co-Dx will showcase its infectious disease and vector control products, along with the upcoming Co-Dx PCR Home testing platform. The company's presentation is scheduled for September 16 at 10:15 am local time.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the H.C. Wainwright & Co. 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Dwight Egan will present on the company’s progress and upcoming Co-Dx PCR Home Diagnostic Platform. The presentation is scheduled for September 13 at 8:30 AM ET, accessible for registered institutional investors. One-on-one meetings with H.C. Wainwright representatives will also be available.